We are monitoring the impact of COVID-19 on Europe Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 1121
Share on
Share on

Europe Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2019 - 2024

Pulished: August, 2019
ID: 1121
Pages: 135

Europe Monoclonal Antibodies Market Size & Growth (2019 - 2024)

According to our report, the Europe Monoclonal Antibodies Market was worth USD 9.63 Billion in 2019 and estimated to be growing at a CAGR of 5.32%, to reach USD 16.37 Billion by 2024.

MAb`s are antibodies produced by a single clone of cells consisting of identical antibody molecules. Monoclonal Antibodies have various diagnostic and therapeutic applications, especially in cancer. Apart from these mAb`s are also useful in protein purification. Growth in sales of currently approved monoclonal antibody products, along with 300 monoclonal antibody products currently in development, will show significant growth in sales of mAb products in the coming five years

Europe Monoclonal Antibodies market is driven by increasing research and development activities, owing to the introduction of advanced methods for mAb production. Major pharmaceutical companies are building their own product pipeline for the development of new molecules. Growing consumer awareness about various benefits and applications of mAb is also a major driving factor for the market growth.

However huge cost and time associated with the identification and development, and stringent regulatory framework are the key restraining factors for the market growth.

This research report has been segmented & sub-segmented into the following categories:

  • By Source: Murine, Chimeric, Humanized and Human
  • By Indication: Cancer (Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer and Others), Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, CNS Disorders and Others (Inflammatory, Microbial Diseases, & Other)
  • By End-User: Hospitals/Clinics, Research Institute and Diagnostic Laboratories
  • By Application: Medical, Experimental, Western Blot (ELISA, Radioimmune Assays, Immunofluorescence and Others)
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

On the basis of source, the Human mAb`s is the largest segment by source accounting for a share of around XX%.

On the basis of end-user, the Hospitals segment is the largest end-user segment accounting for a share of approximately XX%.

Regionally, Europe is the second-largest market for monoclonal antibodies accounting for a share of approximately XX%. Within Europe, Germany is the largest market for monoclonal antibodies followed by the United Kingdom.

Key market participants in the Europe Monoclonal Antibodies Market profiled in this report are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. and Biogen Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 AstraZeneca (U.K.)                  

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Ablynx NV (Belgium)                              

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  2. Europe Chimeric Market By Region, From 2019 - 2024 ( USD Million )
  3. Europe Humanized Market By Region, From 2019 - 2024 ( USD Million )
  4. Europe Human Market By Region, From 2019 - 2024 ( USD Million )
  5. Europe Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  6. Europe Autoimmune Diseases Market By Region, From 2019 - 2024 ( USD Million )
  7. Europe Infectious Diseases Market By Region, From 2019 - 2024 ( USD Million )
  8. Europe Cardiovascular Diseases Market By Region, From 2019 - 2024 ( USD Million )
  9. Europe CNS Disorders Market By Region, From 2019 - 2024 ( USD Million )
  10. Europe Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2019 - 2024 ( USD Million )
  11. Europe Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  12. Europe Research Institute Market By Region, From 2019 - 2024 ( USD Million )
  13. Europe Diagnostic Laboratories Market By Region, From 2019 - 2024 ( USD Million )
  14. Europe Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  15. Europe Experimental Market By Region, From 2019 - 2024 ( USD Million )
  16. U.K. Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  17. U.K. Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  18. U.K. Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  19. U.K. Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  20. Germany Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  21. Germany Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  22. Germany Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  23. Germany Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  24. France Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  25. France Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  26. France Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  27. France Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  28. Italy Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  29. Italy Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  30. Italy Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  31. Italy Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  32. Spain Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  33. Spain Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  34. Spain Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  35. Spain Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  36. Europe Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  37. Europe Breast Cancer Market By Region, From 2019 - 2024 ( USD Million )
  38. Europe Colorectal Cancer Market By Region, From 2019 - 2024 ( USD Million )
  39. Europe Lung Cancer Market By Region, From 2019 - 2024 ( USD Million )
  40. Europe Pancreatic Cancer Market By Region, From 2019 - 2024 ( USD Million )
  41. Europe Others Market By Region, From 2019 - 2024 ( USD Million )
  42. U.K. Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  43. Germany Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  44. France Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  45. Italy Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  46. Spain Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  47. Europe Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  48. Europe ELISA Market By Region, From 2019 - 2024 ( USD Million )
  49. Europe Radioimmune Assays Market By Region, From 2019 - 2024 ( USD Million )
  50. Europe Immunofluorescence Market By Region, From 2019 - 2024 ( USD Million )
  51. Europe Others Market By Region, From 2019 - 2024 ( USD Million )
  52. U.K. Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  53. Germany Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  54. France Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  55. Italy Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  56. Spain Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample